New hope for ALS patients: experimental drug IFB-088 tested in trial

NCT ID NCT05508074

Completed Disease control Sponsor: InFlectis BioScience Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding IFB-088 to standard riluzole treatment is safe and effective for people with bulbar-onset ALS (a form that first affects speech and swallowing). 51 participants received either IFB-088 plus riluzole or a placebo plus riluzole for 6 months. Researchers measured disease progression using functional scales and monitored side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IFB-088 (also called Icerguastat) plus riluzole
What this could lead to: If it works, this could point toward a new treatment option for people with bulbar-onset ALS, potentially slowing disease progression.
What could go wrong: This is an early exploratory trial with only 51 participants, so results may not be conclusive. The drug may show no benefit or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis motor neuron disorder neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA

Marseille, 13385, France
CHU Bretonneau

Tours, 37044, France
CHU de Nantes - Hôpital Laennec

Nantes, 44093, France
CHU de Toulouse - Hôpital Pierre-Paul Riquet

Toulouse, 31059, France
Centro Clinico NeMO per le Malattie Neuromuscolari

Gussago, 25064, Italy
Hôpital Neurologique Pierre Wertheimer

Bron, 69677, France
IRCSS Istituto Neurologico Carlo Besta

Milan, 20133, Italy
Ospedale Civile Sant'Agostino Estense

Baggiovara, 41126, Italy
Sant'Andrea Hospital Unit of Neuromuscular Disorders

Roma, 00189, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.